UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT ~~Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~

~~Date~~Pursuant ofto ~~Report~~Section 13 or 15(~~Date~~d) of ~~earliest~~the ~~event~~Securities ~~reported): September~~Exchange ~~29,~~Act ~~2022~~of 1934

~~Boon~~Date of ~~Industries,~~Report ~~Inc.~~ (~~Exact~~Date ~~name~~ of ~~registrant~~earliest asevent ~~specified~~reported): April in17, ~~charter)~~2023

CuraScientific Corp.

(Exact name of registrant as specified in charter)

Oklahoma		000-56325		84-5079920
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

568 N. Greco Court, San Jacinto, California	92582
51544 Cesar Chavez Street, Coachella, California	92236
(Address of principal executive offices)	(zip code)

~~13340~~Registrant’s telephone ~~Grass Valley Ave~~number, ~~Unit~~including D,area ~~Grass~~code: ~~Valley, California 95945~~ (~~former name or former address, if changed since last report~~909) 435-1642

~~Registrant’s telephone~~Boon ~~number~~Industries, ~~including~~Inc. ~~area code:~~ (~~530)~~Former ~~648-1333~~name or former address, if changed since last report)

110 Spring Hill Road #16, Grass Valley, CA 95945

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 1.01 Entry into a Material Definitive Agreement.

Item 2 3.~~01.~~03 ~~Completion~~Material ofModification ~~Acquisition~~to orRights ~~Disposition~~ of ~~Assets~~Security Holders.

Item 35.0203. ~~Unregistered~~Amendments ~~Sales~~to Articles of ~~Equity~~Incorporation ~~Securities~~or Bylaws; Change in Fiscal Year.

OnPursuant ~~September~~to 29an Agreement and Plan of Merger (“Merger Agreement”), dated as of December 13, 2022, by and between, Boon Industries, Inc., ~~(the~~an Oklahoma corporation (“~~Company~~Boon”), ~~entered~~and ~~into~~CuraScientific Corp., a ~~Share~~Florida ~~Exchange~~corporation ~~Agreement,~~and ~~with~~wholly-owned ~~Cal~~subsidiary ~~Care~~of ~~Grp, Inc.~~Boon (“~~Cal Care~~CuraScientific”), ~~and~~effective ~~William~~as ~~Reed~~of April 17, as2023, ~~the~~Boon ~~sole~~merged ~~shareholder~~with ofand ~~Cal~~into ~~Care~~CuraScientific, with CuraScientific being the surviving entity (the “~~Share~~Reincorporation ~~Agreement~~Merger”). ~~Cal~~The ~~Care~~Reincorporation ~~Grp~~Merger, ~~Inc.~~including the Reverse Stock Split and Name Change isdescribed below, were approved by the written consent of stockholders owning a ~~licensed~~majority ~~delivery~~of ~~and~~the ~~distribution~~voting ~~company~~power ~~with~~of ~~locations~~Boon’s capital stock, as reported in ~~Southern~~the Definitive Information Statement on Schedule 14C filed by Boon with the Securities and ~~Northern~~Exchange ~~California~~Commission on December 19, 2022.

~~The~~Pursuant ~~Share~~to ~~Agreement provides for~~ the ~~acquisition~~terms ~~by the Company~~ of ~~all of~~ the ~~outstanding~~Merger ~~shares~~Agreement ~~of Cal Care from Mr. Reed, who is also the Company’s Chairman~~ and ~~Chief~~as ~~Executive~~a ~~Officer,~~result ~~in consideration~~ of the ~~issuance~~effectiveness ~~to Mr. Reed~~ of ~~500,000 shares of~~ the ~~Company’s Series~~Reincorporation ~~A Preferred Stock.~~Merger:

~~The closing~~● ofBoon ~~the~~merged ~~transactions~~with ~~under~~and ~~the~~into ~~Share~~CuraScientific, ~~Agreement~~with ~~occurred~~CuraScientific onbeing ~~September~~the ~~29,~~surviving ~~2022.~~corporation;

~~The information~~● ~~set~~our ~~forth~~domicile ~~above~~changed isfrom athe ~~summary,~~State ~~and~~of isOklahoma ~~qualified in its entirety by reference~~ to the ~~actual~~State ~~terms~~ of ~~the Share Agreement, which has been filed as Exhibit 10.1 to this Current Report on Form 8-K.~~Florida;

~~Item 5.02~~● ~~Departure~~our ofname ~~Directors~~changed orfrom ~~Certain~~“Boon ~~Officers;~~Industries, ~~Election~~Inc.” ofto ~~Directors;~~“CuraScientific ~~Appointment~~Corp.” of(the ~~Certain~~“Name ~~Officers~~Change”); ~~Compensatory Arrangements of Certain Officers.~~

~~On September~~● ~~29,~~we ~~2022,~~are ~~the~~now ~~Board~~governed ofby ~~Directors~~the laws of the ~~Company~~State ~~appointed~~of ~~Paul~~Florida ~~Goyette~~and toby ~~serve~~CuraScientific’s asArticles aof ~~director~~Incorporation ofand ~~the~~Bylaws; ~~Company.~~and

~~Mr. Goyette,~~● ~~61,~~each is500 anshares ~~attorney~~of ~~that~~common ~~has~~stock ~~been~~of ~~practicing~~Boon ~~law~~was ~~since~~converted ~~1988.~~into Heand isbecame ~~currently~~one ~~the~~validly ~~CEO~~issued, fully paid and nonassessable share of ~~Goyette,~~the ~~Ruano~~common &stock ~~Thompson,~~of ~~Inc.~~CuraScientific, a ~~California~~as ~~based~~further ~~law~~described ~~firm~~below ~~that~~(the he“Reverse ~~founded~~Stock ~~in 1992~~Split”).

InThe ~~connection~~Reincorporation ~~with~~Merger ~~his~~did ~~appointment~~not asresult ain ~~director,~~any ~~Mr.~~change ~~Goyette~~in ~~entered~~our ~~into~~headquarters, abusiness, ~~Board~~management, location of ~~Directors~~our ~~Agreement~~any ~~with~~offices ~~the~~or ~~Company~~facilities, ~~pursuant to~~ ~~which~~number ~~Mr.~~of ~~Goyette~~employees, ~~will~~federal betax ~~paid~~identification ~~a cash fee of $2~~number,~~000~~ ~~per~~assets ~~meeting,~~or ~~and~~liabilities be(other ~~issued~~than ~~$100,000~~as ofa ~~shares~~result of the ~~Company’s~~costs ~~Series~~incident Ato ~~Preferred~~the Reincorporation ~~Stock.~~Merger, ~~The~~which ~~foregoing~~are isnot amaterial). ~~summary~~Management, ~~and~~including isall ~~qualified~~directors inand ~~its~~officers, ~~entirety~~remain ~~by reference to~~ the ~~actual~~same ~~terms~~immediately ofafter the ~~Board of Directors Agreement,~~Reincorporation ~~which has been filed as Exhibit 10~~Merger.~~2 to this Current Report on Form 8-K.~~

~~Other~~The ~~than~~foregoing asdescription ~~set~~of ~~forth~~the ~~above,~~Merger ~~there~~Agreement ~~are~~is nointended ~~arrangements~~to orbe ~~understandings~~a ~~with~~summary ~~Mr.~~and ~~Goyette~~is ~~pursuant~~qualified in its entirety by reference to such agreement, which heis ~~was~~filed ~~appointed~~ as anExhibit ~~officer director~~2.1 ofto ~~the~~this ~~Company,~~Current Report and ~~there~~incorporated ~~are~~by noreference ~~related~~herein. ~~party~~Copies ~~transactions~~of ~~between~~ the ~~Company~~Articles of Incorporation and Bylaws Mrof CuraScientific are filed as Exhibits 3.1 ~~Goyette~~and ~~that~~Exhibit ~~are~~3.2, ~~subject~~respectively, to ~~disclosure under~~this ~~Item~~Current ~~404(a)~~Report ofon ~~Regulation~~Form S8-K (this “Current Report”) and are incorporated by reference herein.

This Current Report is also being filed for the purpose of establishing CuraScientific as the successor issuer to Boon pursuant to Rule 12g-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Pursuant to Rule 12g-3(a) under the Exchange Act, the shares of common stock of CuraScientific Brewing Company, as successor issuer, are deemed registered under Section 12(g) of the Exchange Act.

Additional Trading Information

FINRA Effective Date; Symbol Changes; CUSIP Number. The Reverse Stock Split and Name Change will become effective with FINRA (the Financial Industry Regulatory Authority) and in the marketplace at the open of business on April 24, 2023, whereupon the shares of CuraScientific common stock will begin trading on a split-adjusted basis. On the April 24, 2023, the trading symbol for our common stock will change to “BNOWD” for a period of 20 business days, after which our common stock will trade under our new trading symbol “CSTF”. The CUSIP number for CuraScientific’s common stock is 09858Y208.

Split Adjustment; No Fractional Shares. As a result of the Reverse Stock Split, the total number of shares of our common stock held by each stockholder will be converted automatically into the number of whole shares of CuraScientific common stock equal to (i) the number of shares of Boon common stock held by such stockholder immediately prior to the effectiveness of the Reverse Stock Split, divided by (ii) 500, rounded up (if applicable) to the next whole number. No fractional shares will be issued, and no cash or other consideration will be paid in connection with the Reverse Stock Split. Instead, CuraScientific will issue one whole share of common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split.

Certificates. Stockholders who hold their shares in electronic form do not have to take any action as the effect of the Reincorporation Merger and Reverse Stock Split will automatically be reflected in their accounts. Stockholders holding paper certificates may (but are not required to) send their certificates to the Company’s transfer agent at the address given below. The transfer agent will issue a new share certificate reflecting the terms of the Reverse Stock Split and Name Change to each requesting stockholder.

New Horizon Transfer
215-515 West Pender Street
Vancouver, BC V6B 6H5
Canada
Phone: (604) 876-5526
Facsimile: (604) 876-5564

Immediately after the Reverse Stock Split, each stockholder’s percentage ownership interest in the Company and proportional voting power will remain unchanged except for minor adjustments that may result from rounding fractional shares into whole shares. The rights and privileges of the holders of shares of Common Stock will be unaffected by the Reverse Stock Split.

Item 9.01. Financial Statements and Exhibits.

(a) Financial statements of businesses acquired.

The required financial information will be filed in an amendment to this Current Report on Form 8-K not later than 71 days after the date on which this initial report on Form 8-K must be filed.

(d) Exhibits.

Exhibit 10.1	Share Exchange Agreement, dated September 29, 2022, among Cal Care Grp, Inc., William Reed, and Boon Industries, Inc.
Exhibit 2.1	Agreement and Plan of Merger, dated as of December 13, 2022, by and between, Boon Industries, Inc. and CuraScientific Corp.
Exhibit 10.2	Board of Directors Agreement, dated October 1, 2022, between Boon Industries, Inc. and Paul Goyette
Exhibit 3.1	Articles of Incorporation of CuraScientific Corp.
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
Exhibit 3.2	Bylaws of CuraScientific Corp.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Boon Industries, Inc.
	CuraScientific Corp.
	Date: September 30, 2022
	Date: April 24, 2023
	By:	/s/ William J. Reed
	Name: William J. Reed
	Title: Chief Executive Officer

Filing Compare · CuraScientific Corp.